PDBsum entry 3l13

Go to PDB code: 
protein ligands links
Transferase PDB id
Protein chain
841 a.a. *
* Residue conservation analysis
PDB id:
Name: Transferase
Title: Crystal structures of pan-pi3-kinase and dual pan-pi3-kinase inhibitors
Structure: Phosphatidylinositol-4,5-bisphosphate 3-kinase ca subunit gamma isoform. Chain: a. Fragment: unp residues 144-1102. Synonym: pi3-kinase p110 subunit gamma, ptdins-3-kinase sub pi3kgamma, pi3k, p120-pi3k. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: pik3cg. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108.
3.00Å     R-factor:   0.233     R-free:   0.275
Authors: J.M.Murray,C.Wiesmann
Key ref: D.P.Sutherlin et al. (2010). Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem, 53, 1086-1097. PubMed id: 20050669 DOI: 10.1021/jm901284w
10-Dec-09     Release date:   16-Feb-10    
Go to PROCHECK summary

Protein chain
Pfam   ArchSchema ?
P48736  (PK3CG_HUMAN) -  Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
1102 a.a.
841 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class 2: E.C.  - Phosphatidylinositol-4,5-bisphosphate 3-kinase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]

1-Phosphatidyl-myo-inositol Metabolism
      Reaction: ATP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate
+ 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
+ 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate
   Enzyme class 3: E.C.  - Non-specific serine/threonine protein kinase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: ATP + a protein = ADP + a phosphoprotein
+ protein
+ phosphoprotein
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site
 Gene Ontology (GO) functional annotation 
  GO annot!
  Biological process     phosphatidylinositol-mediated signaling   2 terms 
  Biochemical function     transferase activity, transferring phosphorus-containing groups     2 terms  


DOI no: 10.1021/jm901284w J Med Chem 53:1086-1097 (2010)
PubMed id: 20050669  
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
D.P.Sutherlin, D.Sampath, M.Berry, G.Castanedo, Z.Chang, I.Chuckowree, J.Dotson, A.Folkes, L.Friedman, R.Goldsmith, T.Heffron, L.Lee, J.Lesnick, C.Lewis, S.Mathieu, J.Nonomiya, A.Olivero, J.Pang, W.W.Prior, L.Salphati, S.Sideris, Q.Tian, V.Tsui, N.C.Wan, S.Wang, C.Wiesmann, S.Wong, B.Y.Zhu.
The PI3K/AKT/mTOR pathway has been shown to play an important role in cancer. Starting with compounds 1 and 2 (GDC-0941) as templates, (thienopyrimidin-2-yl)aminopyrimidines were discovered as potent inhibitors of PI3K or both PI3K and mTOR. Structural information derived from PI3K gamma-ligand cocrystal structures of 1 and 2 were used to design inhibitors that maintained potency for PI3K yet improved metabolic stability and oral bioavailability relative to 1. The addition of a single methyl group to the optimized 5 resulted in 21, which had significantly reduced potency for mTOR. The lead compounds 5 (GNE-493) and 21 (GNE-490) have good pharmacokinetic (PK) parameters, are highly selective, demonstrate knock down of pathway markers in vivo, and are efficacious in xenograft models where the PI3K pathway is deregulated. Both compounds were compared in a PI3K alpha mutated MCF7.1 xenograft model and were found to have equivalent efficacy when normalized for exposure.

Literature references that cite this PDB file's key reference

  PubMed id Reference
21048785 J.Werzowa, S.Koehrer, S.Strommer, D.Cejka, T.Fuereder, E.Zebedin, and V.Wacheck (2011).
Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.
  J Invest Dermatol, 131, 495-503.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.